Trends and Technology: Fall 2003

Mary Jane Gore

doi:10.29074/ascls.16.4.249

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Mary Jane Gore

Extract

Trends and Technology welcomes releases and information about new products, services, Web sites, trends, and upcoming events (give us six months lead time for seminars and meetings). If your company has a Web site that you would like for us to review, please send us news for our Online section, or tell us about sites that would interest clinical laboratory scientists. These sites, as well as the new product information, are offered for reader information only. We cannot vouch for them and their presence here does not constitute an endorsement by CLS or ASCLS.

FDA APPROVALS The U.S. Food and Drug Administration has approved the first rapid assay screening test that physicians can use in their offices to help diagnose patients with bladder cancer. The FDA approved Matritech's NMP22® BladderChek™ test, which detects a bladder cancer nuclear matrix protein in urine of patients. Contact (617) 928-0820, ext. 248, or visit www.matritech.com.

NEW PRODUCTS Tecan US has announced a strategic alliance with GE Medical Systems for Tecan's front-end Genesis FE500 Workcell. Together, the two companies plan to enhance clinical diagnostics lab output using Tecan's state-of-the-art robotic equipment to enhance sample flow, coupled by world-class customer service by GE Medical Systems. As a modular, compact front-end automation workcell, the Genesis FE500 combines all pre-analytical functions including pre-sorting, centrifugation, volume check and clot detection, decapping, secondary tube labeling, aliquotting and destination sorting into analyzer racks from a variety of manufacturers. Contact GE Medical Systems Britt Zarling, at (262) 544-3453.

Leica Microsystems introduces the…